A veteran cardiologist recalls the days when atrial‑fibrillation ablations were performed blind, relying only on a surgeon’s “feel” to puncture the heart wall. The lack of three‑dimensional mapping made every case a high‑risk gamble, often ending in life‑threatening complications. Today, visualization technology has turned that nightmare into a routine procedure, and Chinese innovators are racing to make the next leap. At a recent “Doctor‑Enterprise Face‑to‑Face” conference, experts debated whether China’s booming domestic cardiovascular device market should follow foreign‑imposed standards or lean on the deep clinical experience of local doctors. Proponents of standardization argue that clear parameters and visual guidance protect patients and shorten learning curves. Critics warn that rigid, imported protocols ignore the nuanced “feel” that Chinese surgeons have honed over thousands of operations, potentially stifling efficiency and creativity. The discussion highlighted breakthrough home‑grown products: a new pulse‑field ablation catheter that precisely targets errant heart tissue, a biodegradable occluder that disappears after sealing congenital defects, and a trans‑catheter tricuspid repair system that avoids open‑chest surgery. These innovations aim to tackle the nation’s leading killer—cardiovascular disease—by offering safer, less invasive, and more affordable solutions while challenging the long‑standing monopoly of foreign manufacturers. The consensus? Success will come from blending rigorous, visual standards with the seasoned intuition of Chinese clinicians, ensuring that every patient can trust the technology guiding their heart.
Read more